CRT-69 Non Invasive Evaluation Of Cocaine Induced Chest Pain Reduces Cost Compared To Invasive Strategy  by Rajpal, Saurabh et al.
Core Analysis Laboratory, Stanford, CA; 12Erasmus Medisch Centrum, rotterdam,
Netherlands
Aims: To evaluate safety and effectiveness of the Elixir DESyneTM Novolimus-Eluting
Coronary Stent System (CSS) compared to the Endeavor Zotarolimus-Eluting CSS
through assessment of clinical, angiographic, and IVUS endpoints.
Method and Results: 210 patients were randomized 2:1 either to the DESyne CSS
loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via
a durable methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of
stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients
were analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9
months. All patients also underwent evaluation for secondary endpoints which included a
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent
thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents were
also assessed for angiographic endpoints at 9 months including: in-stent and in-segment LLL.
A subset of patients underwent IVUS evaluation including percent neointimal obstruction at
9 months. The study met the non-inferiority endpoint and also demonstrated superiority of the
DESyne CSS as compared to control for in-stent LLL (0.110.32 vs. 0.630.42, p 0.001).
Clinical results through 2 years trend lower for the DESyne stent (4.3% vs, 9.0%, p0.14)
driven primarily by increased TLR fro the Endeavor.
Conclusions: The study met the non-inferiority endpoint and also demonstrated
superiority of the DESyne CSS as compared to control. Clinical results through 3 years
and a review of angiographic and IVUS results will be presented.
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Prevention Of Contrast Induced Nephropathy In Patients Undergoing
Coronarography With Ascorbic Acid
Sonia Hamdi, Wiem Selmi, Aymen Hraiech, Walid Jomaa, Khaldoun Ben Hamda,
Faouzi Maatouk
Cardiology B University Hospital Fattouma Bourguiba Monastir, Monastir, Tunisia
Background: Contrast induced nephropathy (CIN) is an increasing problem in
cardiology invasive imaging, limited by the absence of treatment and few prevention
methods. Anti oxidant benefits of ascorbic acid have been reported by small series but
evidence remains poor.
Aim: To evaluate the effect of ascorbic acid administration in CIN occurrence in patients
undergoing coronarography.
Methods: Patients undergoing coronarography between March and November 2010
were prospectively and blindly randomized to control group receiving a standard CIN
prevention protocol including saline hydration and ascorbic acid group receiving saline
hydration with ascorbic acid (3g 2hours before the procedure then 2g the day after and
next day). We excluded patients requiring hemodialysis, those with acute renal insuffi-
ciency, heart failure with LVEF  40%, digestive resections, and previous contrast
medium injection and aspirin or ascorbic acid intake. Endpoint was occurrence of CIN
defined as a 25% raise of creatinine level 48 to 72 h after coronarography.
Results: Two hundred two patients were included, 95 in control group and 107 in
ascorbic acid group. Mean age was 66 years and 60% were men. Baseline characteristics
were similar between the two groups. Creatinin level before intervention was 98.6  29
mol/l and contrast medium administrated was 71.6  25 ml. CIN occurred in 31
(15.3%) patients. It was significantly lower in ascorbic acid group (10.3% vs 21.1%,
p0.03).
Conclusion: Ascorbic acid showed to reduce CIN incidence in patients undergoing
coronarography compared with saline hydration alone.
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Effect Of Statins In Contrast-induced Nephropathy After Coronary Angiography
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Background: Contrast-induced nephropathy (CIN) is a frequent complication after
coronary angiography. In the exclusion of saline hydration, the effectiveness of other
means of prevention remains unclear, and almost poor. Thanks to its pleotropic effects,
statins have been used in CIN prevention, but data remains controversial.
Objective: To evaluate the benefit of statins in the prevention of CIN after coronary
angiography.
Methods: We used the database of a randomized controlled trial conducted in the
Cardiology B department of Monastir’s Hospital during the period March to
November 2010 to study the effectiveness of ascorbic acid in the prevention of
CIN. Patients undergoing coronary angiography were randomly assigned to a
saline hydration prevention protocol or a saline hydration associated to ascorbic
acid protocol. The primary endpoint was the occurrence of CIN defined as a
creatinin arise of more than 25% the baseline level during the following 48 to 72
hours. The relationship between statin intake at baseline and CIN incidence was
retrospectively evaluated using a Chi-square test.
Results: Among the 202 patients included, 126 (62.3%) were treated with statins. There
was no significant difference between the two groups concerning the baseline character-
istics, particularly in ascorbic acid treatment (p0.94). CIN incidence dropped from
20.8% in the patients not taking statins to 11.7% in those treated with statins. This
resulted in a tendency (p0.08) but difference wasn’t statistically significant, probably due
to the small sample of the population.
Conclusion: In our study, treatment with statins led to a trend to reduce CIN incidence.
The small sample of the population couldn’t allow stronger conclusion. Statins seem to be
promising but larger trials are needed.
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Long-term Comparative Analysis from an All-Comer Cohort of Coronary Patients
Treated Using First and Second Generation Drug Eluting Stents
Pablo Codner, Tamir Bental, Hanna Vaknin-Assa, Eli I. Lev, Abid Asali,
Ran Kornowski
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Background: The long term safety and efficacy of 1st and 2nd generation drug eluting
stents (DES) is of continued clinical importance. We aimed at exploring the potential
differences in clinical outcomes between various DES types.
Methods and Results: We followed 9,584 consecutive patients undergoing PCI at our
institution (years 2004-2012, mean f/u duration 4 years). Patients treated with bare metal
stents 5,599 (58.4%) were compared to 3,985 (41.5%) DES counterparts. The sirolimus
eluting stent (SES) was taken as the prototype DES and compared to other DESs (e.g.
Paclitaxel [P], Zotarolimus-Endeavor [ZE], Zotarolinus-Resolute [ZR], Everolimus [E]
and Biolimus [B] ESs), using propensity matching. Primary outcome was the rate of
composite endpoint of total mortality, MI, clinically driven TVR/CABG. At 3 years, the
composite end point was significantly lower in the DES vs. BMS group (20.0% vs. 26.4%;
P0.001). The comparisons between SES with each one of the 5 other DESs, were very
well balanced and did not yield significant differences for the 3 year primary composite
endpoint: SES vs. PES (n350 pairs; 18.1% vs. 17.7% pNS), SES vs. ZEES (n474
pairs : 21.8% vs. 23.2%, pNS), SES vs. ZRES (n434 pairs; 16.9% vs. 11.7% pNS),
SES vs. EES (n824 pairs; 14.2% vs. 14.1%, pNS) and SES vs. BES (n117 pairs;
13.7% vs. 13.4%, pNS).
Conclusions: We found: 1) no differences in the cardiac prognosis between SES and
other DESs, 2) the use of DES was associated with better clinical outcomes compared to
BMS.
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Non Invasive Evaluation Of Cocaine Induced Chest Pain Reduces Cost Compared To
Invasive Strategy
Saurabh Rajpal, Andres Vargas, Ashish Dwary, Anderson Penuela, Shivang Shah,
Nuri Ilker Akkus
Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA
Purpose: Evaluate the effect of invasive (IT) and non-invasive treatment (NIT)
modalities on hospitalization cost and readmission rate in patients admitted with cocaine
induced chest pain (CICP).
Introduction: As cocaine use has become more widespread, the number of cocaine-
related cardiovascular events and cost of care has increased. A high percentage of patients
with cocaine associated chest discomfort are admitted to the hospital, with an average stay
of three days. A 9-12 hours observation in a chest pain unit has been validated to be safe
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in patients with cocaine-associated chest pain who do not have evidence of ischemia or
cardiovascular complications, but there is no study in literature assessing the cost benefit
and readmission rate of IT vs. NIT in patients with CICP admitted to the hospital.
Methods: Retrospectively data of 83 consecutive patients from 2002-2010 who were
admitted with CICP with positive urine drug screen was analyzed. Cost of admission of
each patient was calculated by including cost of hospital stay, medications, laboratory tests,
EKG, cardiac stress test and left heart catheterization. IT arm included patients who
underwent left heart catheterization (LHC), NIT arm included patients managed
conservatively (with or without stress test). Medical records of these patients were
followed for 2 years to look at the number of readmissions for CICP. A Man-Whitney
U test was calculated to compare cost in the IT vs. NIT. A Chi-square test was done, to
compare the incidence of readmissions between the two groups.
Results: Among patients with CICP, 17 patients underwent IT, 66 patients were
managed conservatively (NIT). Overall, average length of stay was 2.7 days and cost of
hospitalization was $5336.54. Man-Whitney U test revealed that the total hospitalization
cost in the IT group (M-place69.24) was significantly higher (U98.000, p0.001)
than the NIT group (M-place34.98). Median cost in IT group was $8626.06 vs. $3674
in NIT group. 16 patients had at least one readmission in 2 years. Overall, there were 41
re-admissions (Average 0.59 readmissions per person in 2 years). There was no significant
difference in the number of readmission between the IT and NIT groups [Chi-square
(DF1) 1.108, p0.293]
Conclusion: Patient admitted with CICP who were managed conservatively had lower
cost of management and similar number of readmissions compared to subjects who were
managed invasively. Conservative management can be preferred in patients with CICP.
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The Resolute Zotarolimus-eluting Stent Is Equally Safe And Effective In Women And
Men With Coronary Artery Disease: Two-year Outcomes From The Pooled Resolute
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Background: Historically, women with cardiovascular (CV) disease have more comor-
bidities and a higher risk for major CV events and death than men. Outcomes following
percutaneous coronary intervention with new generation drug-eluting stents suggest this
disparity between sexes is decreasing. Nevertheless, there are clear biological differences
between men and women that impact the risk for CV events. Long-term outcomes
following treatment with the Resolute™ zotarolimus-eluting stent (R-ZES) have not
been reported according to sex.
Methods: Patient-level data was pooled from RESOLUTE All Comers (N1140),
RESOLUTE (N139), RESOLUTE US (N1402), RESOLUTE-International
(N2349) and RESOLUTE-Japan (N100) and stratified by sex. Two-year safety
endpoints were compared between the groups after propensity score adjustment for
differences in baseline characteristics. Endpoints include cardiac death, target-vessel
myocardial infarction (TV-MI), clinically-driven target lesion revascularization (TLR),
target-lesion failure (TLF; composite of cardiac death, TV-MI and TLR) and definite/
probable stent thrombosis (ST) through 2 years. All RESOLUTE trials prescribed at least
six months dual antiplatelet therapy.
Results: There were 3,842 men and 1,288 women evaluated. Men were younger (62.8
vs 66.9 yrs, p.001), less likely to have diabetes (27.2% vs 38.0%, p.001) and more like
to have had a prior MI (28.5% vs 20.3%, p.001). Men had longer lesions (15.9 vs 15.1
mm, p.001) a larger pre-procedure diameter stenosis (75.9% vs 74.3%, p.001). At 2
years there was no significant difference in any endpoint between the sexes. TLF was 9.0%
for men vs 10.2% for women; cardiac death plus TV-MI was 5.0% in men and 6.6% in
women. Rates of late and very late ST were 0.2% and 0.1% for men and 0.2% for women
at both timepoints.
Conclusions: When adjusted for baseline differences in clinical and lesion characteristics,
there was no increase in CV events among women treated with R-ZES compared with
men. At 2 years after R-ZES treatment, event rates were low and similar for both men
and women.
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Long-Term Outcomes of Patients with Iodinated Contrast Dye Allergy Undergoing
Diagnostic Angiography and Percutaneous Intervention
Wendy Bottinor,1 Peter Danyi,2 Kalpesh Patel,1 Jeremy Turlington,1 Ion S Jovin1
1Viriginia Commonwealth University, Richmond, VA 2Salem VAMC, Salem, VA
Background: Patients with iodinated contrast dye allergy usually receive premedication
before diagnostic angiography and percutaneous intervention. Whether the contrast dye
allergy or the premedication affects these patients’ risk for contrast-induced nephropathy
or their long-term outcomes is not known. We studied the association between dye allergy
and long-term outcomes in patients undergoing diagnostic angiography and percutaneous
intervention.
Methods and Results: We studied 2713 predominantly (98%) male patients under-
going peripheral and coronary angiography/cardiac catheterization and percutaneous
coronary and endovascular intervention. The mean age was 68 years. A total of 128 (4.7%)
patients had contrast dye allergy. The dye allergy patients had similar baseline creatinine,
and did not differ in medical therapy from the patients without dye allergy. Information
on creatinine at 3 months was available on 1327 patients. Renal dysfunction occurred in
6 (8.82%) patients with dye allergy and 170 (13.5%) in patients without allergy at 3
months after the procedure (odds ratio [OR] 0.62; 95% confidence interval [CI]
0.26-1.46; P0.24). After a follow-up of 60 months, 1 patient (0.78%) of the dye allergy
group was placed on dialysis versus 42 (1.62 %) patients of the group without dye allergy
(OR 0.48, CI 0.07-3.49; P0.46) and 21 patients (16.41%) died of any cause among the
group with dye allergy versus 600 (23.21%) patients of the no allergy group (OR 0.65, CI
0.40-1.05; P0.06). On multivariate analysis, after adjustment for age, comorbidities and
baseline creatinine, dye allergy was not significantly associated with renal dysfunction at 3
months (OR 1.02, CI 0.52-1.99; P0.94), and with starting of dialysis (OR 0.63, CI
0.28-47.69; P0.63) but was significantly and inversely associated with death (OR 0.50,
CI 0.24-0.82; P0.007).
Conclusion: In this cohort of patients, iodinated contrast dye allergy was not associated
with the development of renal dysfunction at 3 months after diagnostic angiography or
percutaneous intervention or of long-term development of end-stage renal disease
requiring dialysis. The association between dye allergy and reduced mortality needs to be
confirmed in a larger cohort.
CRT-72
Radiation Dose During Coronary Angiography: Correlation To Body Mass Index
Ashish Shah,1 Ashesh N Buch,1 Paul K Das,2 Eduardas Subkovas,2
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1University Hospital of Wales, Cardiff, United Kingdom 2Glan Clwyd Hospital,
Bodelwyddan, United Kingdom
Introduction: Coronary angiography (CAG) is a commonly performed procedure in
cardiology, resulting in patients being exposed to radiation. Patients with high body mass
index (BMI) are at increased risk of coronary artery disease. Catheter laboratory
intensifiers use automatic exposure control (AEC) which adjusts radiation dose aiming to
provide optimal quality images. Factors shown to be responsible for dose variability are
complexity of the procedure, operator experience, their level of training in radiation
protection, type and performance of x-ray equipment. The objective of present study was
to evaluate if radiation dose received by patients correlated with BMI.
Method: Retrospective data for 3678 CAG performed from Sep-07 to Mar-10 from a
single centre, were analysed. Radiation dose was calculated as Dose Area Product (DAP)
in mGym2.
Results: Mean radiation dose during the procedure was 4339  286 mGym2. Mean
BMI, contrast volume used and screening time were 29.22 0.08 kg/m2, 125 10.0 ml
and 5.2  0.1 minutes respectively. BMI was positively correlated with increasing
radiation dose during CAG (graph-1 & 2). Patients with increased BMI did not require
prolonged procedure or increased contrast volume. There was no significant inter-operator
variability. Even Ten degree increase in angulation (oblique, cranial or caudal) increased
radiation dose significantly.
Conclusion: Patients with increased BMI receive a significantly higher radiation dose
during CAG, affecting not only the patient, but every one present in the catheter
laboratory. This has to be recognized by the operator when undertaking procedures in
patients with a high BMI.
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